Highlights of This Issue 1479

REVIEWS

1481 Collagen XV: Exploring Its Structure and Role within the Tumor Microenvironment
Anthony George Clementz and Ann Harris

1487 Advances in Understanding the Expression and Function of Dipeptidyl Peptidase 8 and 9
Hui Zhang, Yiqian Chen, Fiona M. Keane, and Mark D. Gorrell

CELL CYCLE AND SENESCENCE

1497 SIRT1 Is Downregulated in Gastric Cancer and Leads to G1-phase Arrest via NF-κB/Cyclin D1 Signaling
Qing Yang, Bo Wang, Wei Gao, Shanying Huang, Zhifang Liu, Wenjuan Li, and Jihui Jia

1508 A Novel Regulatory Mechanism of Pim-3 Kinase Stability and Its Involvement in Pancreatic Cancer Progression
Fei Zhang, Bin Liu, Zhen Wang, Xian-Jun Yu, Quan-Xing Ni, Wen-Tao Yang, Naofumi Mukaida, and Ying-Yi Li

CELL DEATH AND SURVIVAL

1521 Resveratrol and P-glycoprotein Inhibitors Enhance the Anti-Skin Cancer Effects of Ursolic Acid
Jacob J. Junco, Anna Mancha, Gunjan Malik, Sung-Jen Wei, Dae Joon Kim, Huiyun Liang, and Thomas J. Slaga

1530 Hematopoietic Expression of Oncogenic BRAF Promotes Aberrant Growth of Monocyte-Lineage Cells Resistant to PLX4720
Tamihoro Kamata, David Dankort, Jing Kang, Susan Giblett, Catrin A. Pritchard, Martin McMahon, and Andrew D. Leavitt

CHROMATIN, GENE, AND RNA REGULATION

1542 S100A14: Novel Modulator of Terminal Differentiation in Esophageal Cancer
Hongyan Chen, Jianlin Ma, Benjamin Sunkel, Aiping Luo, Fang Ding, Yi Li, Huan He, Shuguang Zhang, Chengshen Xu, Qinge Jin, Qianben Wang, and Zhihua Liu

1544 AKR1B10, a Transcriptional Target of p53, Is Downregulated in Colorectal Cancers Associated with Poor Prognosis
Tomoko Ohashi, Masashi Idogawa, Yasushi Sasaki, Hiromu Suzuki, and Takashi Tokino

DNA DAMAGE AND REPAIR

1564 Systematic Screen Identifies miRNAs That Target RAD51 and RAD51D to Enhance Chemosensitivity
Jen-Wei Huang, Yemin Wang, Kiranjit K. Dhillon, Philamer Calses, Emily Villegas, Patrick S. Mitchell, Munesh Tewari, Christopher J. Kemp, and Toshiyasu Taniguchi

GENOMICS

1574 EGFR Inhibition Induces Proinflammatory Cytokines via NOX4 in HNSCC
Elise V.M. Fletcher, Laurie Love-Homan, Arya Sobhakumari, Charlotte R. Feddersen, Adam T. Koch, Apollina Goel, and Andrea L. Simons

1585 A Proangiogenic Signature Is Revealed in FGF-Mediated Bevacizumab-Resistant Head and Neck Squamous Cell Carcinoma
Rekha Gyanchandani, Marcus V. Ortega Alves, Jeffrey N. Myers, and Seungwon Kim

ONCOGENES AND TUMOR SUPPRESSORS

1597 Activation of the Wnt Pathway through AR79, a GSK3β Inhibitor, Promotes Prostate Cancer Growth in Soft Tissue and Bone
Yuan Jiang, Jinhui Dai, Honglai Zhang, Joe L. Sotnik, Jill M. Keller, Katherine J. Escott, Hitesh J. Sangaree, Zhi Yao, Laurie K. McCauley, and Evan T. Keller
Inhibition of NF-κB Signaling Ablates the Invasive Phenotype of Glioblastoma

PKCι Maintains a Tumor-initiating Cell Phenotype That Is Required for Ovarian Tumorigenesis
Yin Wang, Kristen S. Hill, and Alan P. Fields

ACKNOWLEDGMENT TO REVIEWERS

ABOUT THE COVER
An activating BRAF mutation has been detected in a number of human monocyte/macrophage (histiocyte)-lineage hematopoietic neoplasms. Conditional expression of the activating BRAFV600E mutation in the mouse hematopoietic system induces aberrant growth of monocyte-lineage cells, including solid organ infiltration and a monocytosis in the circulating blood (cover image) reminiscent of human hematopoietic disorders. The mouse model affords a useful preclinical platform for understanding the biology of and developing pathway-targeted therapeutics against human monocyte-lineage hematopoietic neoplasms driven by BRAFV600E expression. For more information see the article by Kamata and colleagues on page 1530.